异基因造血干细胞移植预处理方案选择

The progress in preconditioning regimens in allogeneic HSCT

移植前预处理是造血干细胞移植(HSCT)能否成功的中心环节。在增强预处理抗肿瘤作用与减轻毒副反应、抑制移植物抗宿主病(GVHD)与保留移植物抗白血病效应(GVL)之间取得平衡,从而提高移植后长期生存率,是多年来改进预处理方案的终极目标。应针对不同的疾病、不同的疾病阶段、不同的供体类型和HLA相合程度,制定相应的预处理方案。文章主要以异基因造血干细胞移植(allo-HSCT)治疗髓系肿瘤为例介绍近年来预处理方案研究的主要进展。

Preconditioning is one of the key steps to the success of hematopoietic stem cell transplantation （HSCT）. To en- hance anti-tumor effects while reduce toxicities, to control graft-versus-host disease （GVHD） while prese^we gra^i versus leukemia effect （GVL） ,for the purpose of increasing long-term survival rate after transplantation, is the ultimate goal for many years in the efforts to improve preconditioning regimens. No best conditioning regimens exit for all the diseases. It shouht be designed according to different diseases,disease stages,donor types and HLA matching status as well as patients＇ other characteristics. This paper reviewed major progress in preconditioning regimens in allogeneic HSCT （allo-HSCT） , tak- ing myeloid tumor treatment as an example.